医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

OSAKA, Japan

Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502) today announced the appointment of James Kehoe as Takeda’s new Chief Financial Officer and Corporate Officer, effective on June 15, 2016. Mr. Kehoe will be based in Tokyo and reports directly to Christophe Weber, President & CEO of Takeda.

“James Kehoe’s passion for transforming large organizations to achieve higher performance will hold him in good stead as he leads the Global Finance team to further elevate the company’s business performance and help Takeda deliver its growth ambitions,” said Christophe Weber, President & CEO of Takeda. “We also believe that James’s values are very much aligned with Takeda’s values and that his personal style will work well with the Takeda Executive Team and the Finance Leadership Team.”

Mr. Kehoe is an accomplished finance executive from the Consumer Goods sector. He is a strong business leader, with a track record of improving operational business performance that includes process optimization. He joins Takeda from Kraft Foods Group in the U.S., where he most recently held the role of CFO. Prior to that, he has held a number of finance-related positions spanning the course of more than 20 years, with assignments based in Germany, Switzerland and Italy.

An Irish national, Mr. Kehoe holds a Bachelor of Commerce degree from the University College, Galway, Ireland, and an MSc in Finance from the University College Dublin, Ireland.

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited is a global, R&D-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its research efforts on oncology, gastroenterology and central nervous system therapeutic areas. It also has specific development programs in specialty cardiovascular diseases as well as late-stage candidates for vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as its presence in emerging markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit http://betterhealth.takeda.com/.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160511006679/en/